Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 10/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840183 | 0.85 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL8185921 | 0.79 | CHRNB2 (0.43) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL22565594 | 0.79 | NR1H2 (0.58) | CHRNB2CHRNA3CHRNA4CHRNB4JAK1 | |
| SCHEMBL22565600 | 0.79 | NR1H2 (0.58) | CHRNB2CHRNA3CHRNA4CHRNB4JAK1 | |
| SCHEMBL8145007 | 0.77 | L3MBTL3 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL20808277 | 0.77 | L3MBTL3 (0.45) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3 | |
| SCHEMBL6969158 | 0.76 | HTR6 (0.35) | — | |
| SCHEMBL26496895 | 0.75 | L3MBTL3 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNB3 | |
| SCHEMBL26496894 | 0.75 | L3MBTL3 (0.41) | CHRNB2CHRNA3CHRNA4CHRNB4CHRNA7 | |
| SCHEMBL12864612 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| EP-1106615-B1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | OKUMURA YOSHIYUKI (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1106615-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176445-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CHRNB2 1149/4885CHRNA3 942/4885CHRNA4 634/4885 |
| US-20020042421-A1 | Substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, HRH4 | CHRNB2 1091/4885CHRNA3 1100/4885CHRNA4 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.